New York, August 6, 2026
WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC (VCT), a clinical research technology company providing subject registry solutions designed to strengthen patient safety, protocol compliance and clinical trial data integrity. The transaction brings together WindRose, a healthcare-focused private equity firm with approximately $8 billion under management, and VCT, whose technology is used by pharmaceutical sponsors, contract research organizations (CROs) and clinical research sites to identify duplicate enrollment and other potential protocol violations. Financial terms of the recapitalization were not disclosed. As part of the transaction, WindRose will appoint Howard Miller as Chief Executive Officer of VCT, while company co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will remain actively involved in supporting the business and its long-term growth strategy.
WindRose Investment Targets VCT Platform Expansion
The investment is expected to support VCT’s continued expansion and development of additional data and analytics capabilities as demand grows for technologies that improve oversight throughout clinical research. VCT has spent approximately 16 years developing proprietary data assets and processes focused on protecting clinical trial participants and strengthening the integrity of study data. Its secure global database provides research organizations with a mechanism to verify trial participants and identify potential duplicate enrollment or other protocol-related concerns. Preventing inappropriate simultaneous or overlapping participation in clinical studies can be important for both patient safety and reliability of clinical trial results, particularly when participation could introduce confounding factors or increase safety risks. With WindRose’s financial backing and healthcare investment expertise, VCT plans to expand its platform and strengthen its position among pharmaceutical companies, CROs and clinical research sites. The investment also provides resources for VCT to pursue additional analytics capabilities intended to identify and reduce downstream risks during clinical development.
Leadership Transition Supports VCT’s Next Growth Phase
Alongside the recapitalization, Howard Miller will become Chief Executive Officer of Verified Clinical Trials, bringing leadership experience focused on scaling high-growth businesses and developing organizational capabilities. VCT’s founders, Mitchell Efros and Kerri Weingard, will continue to participate in the business, providing continuity as the company enters its next stage of development. The founders said the partnership is intended to help establish VCT’s subject verification solution as a standard for clinical trial compliance, supporting sponsors, CROs and research sites as they work to conduct safer and more reliable studies. WindRose views VCT’s platform as a differentiated solution capable of proactively reducing risks that can otherwise result in trial disruptions, compromised data quality or participant safety concerns. Further investment in the company’s technology and capabilities could broaden the role of subject verification and data analytics throughout the clinical development process, from patient enrollment through study completion.
Advertisement
Deal Highlights Investment in Clinical Trial Data Integrity
The recapitalization comes as pharmaceutical developers and CROs increasingly focus on clinical trial quality, regulatory compliance, patient safety and reliable data collection. Clinical studies depend on adherence to eligibility requirements and study protocols, making systems capable of detecting duplicate enrollment and related violations potentially valuable for maintaining research integrity. VCT’s global registry is designed to provide research organizations with an additional layer of oversight while helping prevent avoidable protocol deviations before they affect study outcomes. WindRose’s investment positions VCT to accelerate adoption of its clinical trial compliance platform while developing new data and analytics capabilities for customers across the pharmaceutical research ecosystem. The transaction was supported by Cantor Fitzgerald & Co., which served as exclusive financial advisor to VCT. McDermott Will & Schulte LLP served as legal advisor to VCT, while Latham & Watkins LLP advised WindRose. Although financial terms were not disclosed, the completed recapitalization represents a significant strategic transaction for the clinical research services sector. For WindRose, the investment aligns with its strategy of backing healthcare services companies offering cost-effective solutions. For VCT, the partnership provides additional resources to scale technology designed to protect research participants, strengthen protocol compliance and improve clinical trial data integrity, potentially supporting more efficient development of new therapies.
Source: WindRose Health Investors, Verified Clinical Trials press release
